My watch list  

39 Current news of Johnson & Johnson


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

Phase 1/2a Clinical Trial to Begin in Second Half of July


Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is ...


Johnson & Johnson Announces Expected Settlement of Actelion Tender Offer


Johnson & Johnson announced that, with today's receipt of approval of the proposed acquisition of Actelion Ltd from the European Commission (EC), all regulatory approvals required to complete the transaction have been received. Johnson & Johnson expects the settlement of the all-cash public ...


Johnson & Johnson and Actelion end discussion about strategic transaction


Johnson&Johnson confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders. Actelion has taken note of the announcement by Johnson ...


Johnson & Johnson announces completion of Novira Therapeutics, Inc. acquisition


Johnson & Johnson announced the completion of the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The transaction was originally announced on November 4, ...


FDA approves new therapy for certain types of advanced soft tissue sarcoma


The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for ...


Johnson & Johnson Announces $10 Billion Share Repurchase Program


Johnson & Johnson announced that its Board of Directors has approved the repurchase of up to $10 billion of the company's common stock. "We are pleased that Johnson & Johnson's strong balance sheet and cash flow enable us to simultaneously return value to shareholders through our regular ...


LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives


The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate drug candidates for the treatment and prevention of diseases with high unmet medical needs.Over a two-year period, LDC and the team from the Johnson & Johnson’s London ...


Collaboration between Janssen and USAID to Expand Access to Anti-Multidrug-Resistant Tuberculosis Compound


Johnson & Johnson announced that its affiliate Janssen Therapeutics, Division of Janssen Products, LP (Janssen), has signed a Memorandum of Understanding (MOU) representing the intention of the Company along with the United States Agency for International Development (USAID) to step up the fight ...


Johnson & Johnson Announces Completion of Synthes Acquisition


Johnson & Johnson announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock. Synthes will now be integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson.Under the terms of the agreement, ...


Johnson & Johnson Acquires 98.89% of Issued Crucell Shares


Johnson & Johnson and Crucell N.V. announced that following the end of the subsequent offering period (na-aanmeldingstermijn, Subsequent Offering Period), Johnson & Johnson has acquired 98.89% of the issued Shares in Crucell N.V. (Crucell) (which includes treasury shares held by Crucell) and ...


Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE